AUPH — Aurinia Pharmaceuticals Inc
Is AUPH overbought or oversold? Here is the current MarketMoodz read.
Aurinia Pharmaceuticals Inc (AUPH) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $15.83. The rating moved from Neutral to Oversold on October 1, 2026.
- Public ratingOversold (as of October 3, 2026)
- Last close$15.83
- Last changeMoved from Neutral to Oversold on October 1, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Aurinia Pharmaceuticals Inc (AUPH) is a specialty biotech reliant on commercial performance of its marketed therapy and future pipeline/regulatory milestones. Near-term prospects are muted by a risk-off market backdrop and heightened payer/pricing scrutiny that could pressure revenue and margins. Upside scenarios require sustained commercial traction, positive clinical or label news, or supportive strategic financing; downside scenarios center on pricing pressure, clinical setbacks, or the need to raise capital in an uncertain market. Public filing and social sentiment data are limited, so monitor upcoming sales releases, cash runway disclosures, and policy developments closely.
Key factors
- Aurinia Pharmaceuticals Inc (AUPH) commercial execution and revenue trajectory for its marketed therapy (primary near-term cash flow driver).
- Pipeline and regulatory catalysts (potential label expansions, clinical readouts) that would materially change revenue/profit expectations.
- Payer and pricing pressure, including ongoing U.S. Medicare negotiation dynamics that could compress pricing or access for specialty drugs.
- Investor appetite for select specialty biotech and late-stage biologics, which can provide valuation support or enable capital raises from strategic investors.
- Balance sheet and cash runway considerations (need for additional funding would dilute existing holders unless offset by strong sales or partnerships).
- Current market risk-off tone and geopolitical headlines reducing conviction for directional moves absent fresh company-specific catalysts.
Risks
- Adverse Medicare drug-price negotiation outcomes or payer restrictions that reduce pricing, reimbursement, or patient access.
- Slower-than-expected commercial uptake or persistent sales weaknesses for the marketed product(s).
- Clinical or regulatory setbacks in the pipeline that diminish future revenue potential or raise development costs.
- Need to raise capital in a risk-off market, leading to dilution or onerous financing terms.
- High sector volatility where specialist biotech flows can reverse quickly, amplifying share price swings.
- Supply chain or manufacturing disruptions that impede product availability or increase costs.
- Limited public filing and social sentiment data increasing uncertainty around near-term fundamentals.
See today's live rating, score and targets
Members see the live hourly rating for AUPH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.